These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25608713)

  • 1. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
    Coughlan M; Elstrom R
    Cancer Imaging; 2014 Nov; 14(1):34. PubMed ID: 25608713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
    Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
    PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.
    Fuertes S; Setoain X; Lopez-Guillermo A; Carrasco JL; Rodríguez S; Rovira J; Pons F
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):496-504. PubMed ID: 23344136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.
    Ellmann A
    Transfus Apher Sci; 2013 Aug; 49(1):40-2. PubMed ID: 23769694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse large-cell lymphoma in the use of both intermediary staging and at the end of standard chemotherapy].
    Trnený M; Belohlávek O; Koren J; Pytlík R; Sálková J; Klener P
    Vnitr Lek; 2007 Sep; 53(9):936-41. PubMed ID: 18019661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
    Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
    Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
    Roland V; Bodet-Milin C; Moreau A; Gastinne T; Mahé B; Dubruille V; Maisonneuve H; Juge-Morineau N; Moreau P; Jardel H; Planche L; Mohty M; Moreau P; Harousseau JL; Kraeber-Bodéré F; Le Gouill S
    Bone Marrow Transplant; 2011 Mar; 46(3):393-9. PubMed ID: 20577223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
    Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):810-3. PubMed ID: 23384899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
    Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
    Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.
    Kostakoglu L; Nowakowski GS
    PET Clin; 2019 Jul; 14(3):307-315. PubMed ID: 31084771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
    Paksi M; Demeter J; Szabó P
    Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.